Navigation Links
Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
Date:11/13/2007

MOORESVILLE, N.C., Nov. 13 /PRNewswire-FirstCall/ -- Anpath Group, Inc. (OTC Bulletin Board: ANPG), reported today that its wholly-owned subsidiary, EnviroSystems, Inc. (ESI) announced the selection of its disinfectant, EnviroTru(TM) for use by the Washington Metropolitan Area Transit Authority (Metro).

EnviroTru(TM) is a multi-purpose disinfectant and deodorizing cleaner effective against numerous organisms, and also meets EPA requirements for Toxicity Category IV (no harmful dermal, ocular, inhalation or ingestion effects). ESI reported that Metro recently placed an initial order for more than 600 gallons of the disinfectant.

"It is especially gratifying for our product/technology to be chosen by the transit system serving our Nation's Capital", stated ESI President and CEO, J. Lloyd Breedlove. Mr. Breedlove continued, "EnviroTru(TM) is ideally suited for use in a transit system environment. As a result of its biocidal efficacy combined with its favorable materials compatibility and environmental profile EnviroTru(TM) is a natural choice for heavy traffic areas".

Metro is the tri-jurisdictional government agency authorized by Congress to operate the transit service in the Washington, DC metropolitan area, including the Metrorail and Metrobus; totaling more than 11,000 rail cars, buses and special means transport vehicles. Metro is also part of the public- private partnership that operates the DC Circulator bus system. Polly Hanson, Assistant General Manager of Safety, Security and Emergency Management with Metro stated, "We are pleased to have identified and selected a product with the characteristics of EnviroTru(TM). It is important that we make every effort to protect our customers and employees against the spread of infectious diseases without exposing them to harmful chemicals, while also taking into account our equipment and the environment in general."

ESI stated that in addition to daily application of EnviroTru(TM) on high hand contact areas such as door handles, hand rails, fare card machine buttons, etc., in the event of a pandemic flu or other infectious disease outbreak Metro is prepared to use EnviroTru(TM) with the Foster-Miller, Inc. Electrostatic Charged Aerosol Decontamination System (ECADS) (http://www.fostermiller.com/ecadsproduct.htm) to spray rail cars, buses and other vehicles daily. ESI worked with Foster-Miller, Inc. to validate the use of its disinfectant with ECADS.

According to Foster-Miller, Inc. representative, Rick Lusignea, "Metro purchased 17 high efficiency air assisted ECADS sprayers from Foster-Miller to dispense EnviroTru(TM)". Mr. Lusignea explained, "The ECAD decontamination and remediation system disperses fine electrically charged droplets of decontaminant into the air. Because of the static charge imparted to aerosol particles, ECADS provides a much higher amount of disinfectant on surfaces than conventional air assisted spray systems, approximately 60% of the total disinfectant dispensed on the surface for the ECADS sprayer, versus less than 15% for conventional sprayers. We think the combination of our ECADS devices and the ESI disinfectant formulation is an extremely strong weapon against disease for Metro."

About Anpath Group, Incorporated:

Anpath Group, Inc., through its wholly-owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks - both natural and man-made.

Forward Looking Statements:

This release contains forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA registration of the Company's products, the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no duty to update its outlook or other forward-looking statements as of any future date.


'/>"/>
SOURCE Anpath Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):